All-Cause Mortality over 16 Years in Look AHEAD
In this medfyle
Expert Commentary by Martin Haluzík, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ADA 2020 - 80th Scientific Sessions and presented by:
Rena R. Wing, PhD
Weight Control and Diabetes Research Center, Brown University, Providence, RI, USA; and the Look Ahead Group
The content is produced by Infomedica, the official reporting partner of ADA 2020 Virtual Meeting. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Dana M. Dabelea, MD, PhD, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Martin Haluzík, MD
Professor of Internal Medicine, Institute for Clinical and Experimental Medicine, Prague and Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
About the Expert
Martin Haluzík, MD
Professor of Internal Medicine, Institute for Clinical and Experimental Medicine, Prague and Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Martin Haluzík is a Professor of Internal Medicine, Deputy Director of the Diabetes Centre of the Institute for Clinical and Experimental Medicine in Prague and Head of the Metabolic Research Group at the Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague.
Professor Haluzík’s main areas of clinical expertise include diabetology, obesitology and general internal medicine. The major focus of his research concerns the aetiopathogenesis of obesity, insulin resistance and type 2 and type 1 diabetes. Professor Haluzík has special interests in the endocrine function of adipose tissue, the incretin system, novel hormonal factors involved in the regulation of energy homeostasis and glucose metabolism, and the use of novel technologies and therapeutics in the treatment of diabetes. He has been a global expert panel member and national leader for numerous clinical trials with novel antidiabetic drugs including the HARMONY, the PIONEER 1, the LEADER, the SCORED and the SOUL trial.
He is a Co-Editor in Chief of Journal of Endocrinology and Journal of Molecular Endocrinology. He has published over 250 papers in journal with IF. His current H-index is 43.
